Video
Author(s):
Dr Khushalani provides insights into real-world data that was recently discussed at ESMO 2022 assessing the use of cemiplimab in patients with advanced cSCC.
FDA Accepts Resubmission of BLA for Cosibelimab in Locally Advanced or Metastatic CSCC